SVB Wealth LLC purchased a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,819 shares of the company’s stock, valued at approximately $556,000.
Other hedge funds have also recently added to or reduced their stakes in the company. Hughes Financial Services LLC acquired a new position in AstraZeneca during the 4th quarter worth approximately $34,000. Fairscale Capital LLC acquired a new stake in shares of AstraZeneca in the 4th quarter valued at approximately $37,000. Bell Investment Advisors Inc acquired a new stake in shares of AstraZeneca in the 1st quarter valued at approximately $39,000. Mascoma Wealth Management LLC purchased a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $46,000. Finally, Aventus Investment Advisors Inc. acquired a new position in AstraZeneca during the first quarter worth $46,000. Institutional investors and hedge funds own 40.87% of the company’s stock.
AstraZeneca Stock Performance
OTCMKTS:AZNCF opened at $187.10 on Thursday. The stock has a fifty day moving average price of $187.10 and a two-hundred day moving average price of $186.19. AstraZeneca PLC has a 1 year low of $122.26 and a 1 year high of $195.00.
About AstraZeneca
AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.
The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.
Featured Stories
- Five stocks we like better than AstraZeneca
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Want to see what other hedge funds are holding AZNCF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (OTCMKTS:AZNCF – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
